GemVax Confirms Key Mechanism of GV1001 in Alzheimer's Disease...Published in International Journal View original image

On June 10, GemVax & KAEL announced that a research paper elucidating the main mechanism of action of its Alzheimer's disease drug candidate 'GV1001' has been published in the latest issue of the international journal 'Experimental & Molecular Medicine'.


'Experimental & Molecular Medicine' is an SCIE-level international journal co-published by the globally renowned academic publisher Nature Portfolio and the Korean Society for Biochemistry and Molecular Biology. The journal is recognized as an authoritative publication, ranking within the top 5% worldwide in the fields of biochemistry, molecular biology, and experimental medicine according to the JCR, a global academic journal evaluation index.


This research was conducted by the team led by Professor Seongwoon Yoo at Daegu Gyeongbuk Institute of Science and Technology (DGIST). The title of the paper is "Human Telomerase Reverse Transcriptase-Derived Peptide GV1001 Restores Neurodegeneration in an Alzheimer's Disease Mouse Model."


According to the study results, administering GV1001 to an Alzheimer's disease animal model for eight weeks led to a reduction in amyloid plaques, which form when the toxic protein amyloid-beta (Aβ) accumulates between brain nerve cells. At the same time, improvements were observed in memory impairment and synaptic loss. The researchers also confirmed that GV1001 is capable of crossing the blood-brain barrier and directly reaching brain tissue.


Notably, this study found that GV1001 does not directly inhibit amyloid-beta production; instead, it activates microglia, the brain's immune cells, prompting them to remove amyloid plaques. The larger the plaque, the more microglia gathered, resulting in a greater removal effect, and a trend toward reduced neuroinflammatory response was also observed.


Genetic analysis revealed that GV1001 induces microglia to transition into a more activated state known as "disease-associated microglia stage 2 (DAM2)." DAM2 cells migrate toward amyloid plaques and exhibit enhanced phagocytic activity to absorb and break down toxic proteins. The research team analyzed that GV1001 promotes this cellular transition, thereby facilitating plaque removal.


The study also identified signal transduction pathways at the molecular level. The researchers confirmed that GV1001 binds to bradykinin receptor 1 (B1R), subsequently activating the 'mTORC2-AKT1' signaling pathway, which in turn promotes microglial migration and phagocytic activity. Consequently, the 'B1R-mTORC2-AKT1' axis was proposed as one of the main mechanisms of action for GV1001.


A GemVax official stated, "This research is significant in that it newly elucidates the potential mechanism of action for GV1001 in Alzheimer's disease. The approach of directly removing toxic proteins and alleviating neuroinflammation by harnessing brain immune cells differentiates it from existing therapies, reaffirming GV1001's competitiveness as a multi-mechanism therapeutic agent."



This study is being recognized for expanding the therapeutic potential of GV1001 by demonstrating that it is involved in amyloid plaque removal and neuroinflammation alleviation through microglial activation, thereby advancing the development of treatments for Alzheimer's disease.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing